Category: Non-Small Cell Lung Cancer (NSCLC)

  • Atezolizumab

    Description

    This page contains brief details about the drug atezolizumab, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

    Date of Approval

    Atezolizumab is an anticancer drug belonging to the group of medicines called Programmed death ligand – 1 inhibitor (PDL-1). It was officially approved for its medical use in the year 2016.

    Mechanism of Action of Atezolizumab

    Atezolizumab is a humanized monoclonal antibody that belongs to the category of programmed death ligand – 1. Programmed death ligand is a protein that facilitates the suppression of T-cells by binding with immune and tumor cells. This leads to a poor immune response against cancer cells. Atezolizumab Injection acts against the signals of programmed death ligand – 1 and improves immune response by exhibiting specific cytotoxic activity.

    Uses of Atezolizumab

    Atezolizumab is indicated for various types of cancer as a monotherapy and also along with other anticancer medications. It is usually prescribed to treat urothelial carcinoma, liver cancer (hepatocellular carcinoma), small cell and non-small cell lung cancer, triple-negative breast cancer, and melanoma.

    Atezolizumab Dosage available

    Atezolizumab Injection is intended for intravenous administration. Your physician will inject this medicine as an infusion for the first 60 minutes and if it is well tolerated, the subsequent infusions will be administered for 30 minutes.

    Atezolizumab Injection is available as a single-use vial in doses 840mg/14ml and 1200mg/20ml. The ideal dosing for urothelial carcinoma, non-small cell and small cell lung cancers, hepatocellular carcinoma, and melanoma is 840mg every two weeks, 1200mg every 3 weeks, or 1680mg every four weeks.

  • Ceritinib

    Description

    This page contains brief details about the drug ceritinib, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

    Date of Approval

    Ceritinib is a targeted cancer therapy drug belonging to the class of tyrosine kinase inhibitors. It was approved for its medical use on 29th April 2014.

    Mechanism of Action of Ceritinib

    Ceritinib Capsule is indicated to treat the advanced stage of lung cancer as an initial treatment and is also recommended when anticancer treatment with Crizotinib did not work. It is prescribed to treat non-small cell lung cancer caused by defects in the ALK-positive genes.

    Uses of Ceritinib

    Ceritinib Capsule is a biological agent that acts as targeted drug therapy in cancer treatment. It is classified as a tyrosine kinase inhibitor. Anaplastic lymphoma kinase is a significant gene that result in non-small cell lung cancer by undergoing mutation. Ceritinib inhibits ALK genes and stops the growth and development of cancer cells by shrinking them.

    Ceritinib Dosage available

    Ceritinib is available in the form of hard gelatin capsules in a dose of 150mg. The recommended dose is three 150mg capsules once daily. It is advisable to take this medicine simultaneously each day with or without food. Swallow the capsule and do not crush, open, or dissolve them.

  • Vinorelbine

    Description

    This page contains brief details about the drug vinorelbine, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

    Date of Approval

    Vinorelbine is a chemotherapy medication that was approved to be used in 1994.

    Mechanism of Action of Vinorelbine

    Vinorelbine works by inhibiting the microtubule structures within the cell. Microtubule structures help cancer cells to divide and multiply. Inhibition of these structures slows the growth and multiplication of cancer cells.

    Uses of Vinorelbine

    Non-small cell lung cancer (NSCLC)

    Breast cancer

    Vinorelbine Dosage available

    Vinorelbine is available as solution for infusion in two doses of 10mg and 50mg.

  • Trametinib

    Description

    This page contains brief details about the drug trametinib, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

    Date of Approval

    Trametinib was approved by the U.S. Food and Drug Administration (FDA) in May 2013 for treating unresectable or metastatic melanoma.

    Mechanism of Action of Trametinib

    Trametinib is a medication called a mitogen-activated protein kinase (MAPK) kinase inhibitor. It inhibits the activity of the MEK enzyme, which is part of the MAPK pathway that is overactive in many cancer cells. In normal cells, the MAPK pathway plays an important role in regulating cell growth, differentiation, and survival. This pathway can become overactive and contribute to uncontrolled cell growth and tumour formation. It blocks the activity of the MEK enzyme, which is a key component of the MAPK pathway. Doing so helps slow down or stop the growth and spread of cancer cells with these specific genetic mutations. This can lead to a reduction in the size of tumours and an improvement in symptoms for patients with advanced or metastatic cancers.

    Uses of Trametinib

    Unresectable or metastatic melanoma

    Non-small cell lung cancer in combination with Dabrafenib

    Advanced or metastatic thyroid cancer

    Metastatic solid tumours

    Trametinib Dosage available

    Trametinib is typically administered orally as a tablet or capsule taken by mouth. The dose and frequency of it will depend on the specific type of cancer being treated and the patient’s health status. For the treatment of melanoma, trametinib is usually taken once daily, either with or without food. It may be taken simultaneously as dabrafenib, another targeted therapy drug used in combination with trametinib for melanoma. In the management of non-small cell lung cancer, trametinib is usually taken once daily, at the same time as dabrafenib.

  • Lorlatinib

    Description

    This page contains brief details about the drug lorlatinib, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

    Date of Approval

    Lorlatinib is a targeted cancer medication that was approved for its medical use on 2nd November 2018.

    Mechanism of Action of Lorlatinib

    Lorlatinib Tablet is a biological agent that acts as targeted drug therapy in cancer treatment. It is classified as a kinase inhibitor and comes under the class of ALK and ROS-1 inhibitor. Anaplastic Lymphoma Kinase and ROS proto-oncogene are the two genes that promote cellular proliferation and tumour growth in non-small cell lung cancer by undergoing mutation. It works by inhibiting the cell signaling of these genes, ultimately inhibiting tumour growth.

    Uses of Lorlatinib

    Lorlatinib Tablet has been developed to treat adults with Non-small cell lung cancer (NSCLC) that resulted due to mutation in Anaplastic Lymphoma Kinase and ROS-1 genes and has spread to other parts of the body.

    Lorlatinib Dosage available Your doctor will decide the dose and duration of Lorlatinib based on the disease condition and other factors. Take the tablet at the same time everyday, with or without food. Do not chew, crush, or break the tablet. Swallow the whole tablet with water. If you forgot to take the tablet, simply take your next dose at the scheduled time. Do not take a double dose to make up for a forgotten dose.

  • Durvalumab

    Description

    This page contains brief details about the drug durvalumab, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

    Date of Approval

    Durvalumab is an anticancer drug that belongs to the category of medicines known as Anti-PD-1 monoclonal antibodies. It was approved by the FDA in May 2017 to treat certain types of cancer.

    Mechanism of Action of Durvalumab

    It works by blocking a protein called programmed death-ligand 1 (PD-L1), which is found on the surface of certain cancer cells. When PD-L1 binds to its receptor on T cells, it can inhibit the immune system’s ability to recognize and attack cancer cells.  By blocking the interaction between PD-L1 and its receptor, durvalumab allows T cells to recognize and attack cancer cells more effectively. Durvalumab helps the immune system to fight the cancer and potentially slow or stop its growth.

    Uses of Durvalumab

    Durvalumab is used to treat non-small cell lung cancer(has not spread outside your chest ), small cell lung cancer(has spread within your lungs), and biliary tract cancers(cancer of the bile ducts).

    Durvalumab Dosage available

    Durvalumab is a prescription drug available in injection form. This injection will be given intravenously into a vein in your arm or hand by a healthcare professional in a hospital setting. Do not self-administer this medicine. The dose of the injection will be decided by your doctor based on your disease condition and other factors. During the infusion, you will be monitored for any side effects or reactions to the medication. The infusion usually takes a few hours to complete, and you may need to receive multiple infusions over the course of several weeks.

  • Gemcitabine

    Description

    This page contains brief details about the drug gemcitabine, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

    Date of Approval

    The U.S. FDA approved Gemcitabine as a chemotherapeutic anticancer medication to treat bladder, breast, ovarian, pancreatic, and non-small cell lung cancers on 10th January 1995.

    Mechanism of Action of Gemcitabine

    Gemcitabine is a cytotoxic agent belonging to the category of medications called antimetabolites. It inhibits DNA polymerase enzyme, breaks the DNA strands, interferes with cell signalling and eventually prevents the multiplication of cancer cells. Gemcitabine is prescribed alone and also in combination with other anticancer medications like Cisplatin and Carboplatin.

    Uses of Gemcitabine

    Gemcitabine has been developed to treat ovarian cancer, breast cancer, non-small cell lung cancer, and pancreatic cancer in patients who have failed to respond to previous therapies.

    Gemcitabine Dosage available

    Gemcitabine is available for administration as an intravenous infusion that is injected through the veins of patients with ovarian, breast, and non-small cell lung cancer. Your physician will choose the dosage and administration frequency based on your medical condition and type of cancer because it differs for each person.

  • Ramucirumab

    Description

    This page contains brief details about the drug ramucirumab, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

    Date of Approval

    Ramucirumab is an anticancer medication containing the active ingredient Ramucirumab. It is a monoclonal antibody drug. Cancer is a condition in which cells multiply uncontrolled and abnormally. This medication treats advanced stomach, colon, rectum, lungs, and liver cancers. It may be given alone or in combination with other anticancer medications to treat various types of cancer. The benefits of Ramucirumab are that it can help to slow down the growth and spread of cancer cells in various types of cancer. Studies have shown that this medication can improve survival rates and increase the time until cancer progresses to the advanced stage.

    Ramucirumab was approved by the United States Food and Drug Administration (FDA) in April 2014 for the treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma, as well as for the treatment of metastatic non-small cell lung cancer (NSCLC) in combination with other anticancer drug.

    Mechanism of Action of Ramucirumab

    It works by targeting and inhibiting the action of a protein called vascular endothelial growth factor receptor 2 (VEGFR2), which plays a key role in the growth and development of blood vessels that feed tumors. By blocking VEGFR2, ramucirumab helps to prevent the growth and spread of cancer cells.

    Uses of Ramucirumab

    Ramucirumab is used to treat several types of cancer, including advanced gastric cancer or gastroesophageal junction adenocarcinoma, non-small cell lung cancer, hepatocellular carcinoma, and colorectal cancer.

    Ramucirumab Dosage available

    A healthcare professional administers Ramucirumab through intravenous injection in a hospital or clinic setting. It is not intended for self-administration. The recommended dosage and frequency depends on the type and stage of the cancer being treated, the individual patient’s medical history, and overall health status. The drug is usually administered with chemotherapy or as a standalone treatment. If you miss a scheduled dose, contact your healthcare provider as soon as possible to discuss the best course of action. Sometimes, your healthcare provider may recommend that you receive the missed dose as soon as possible and then resume the regular dosing schedule. However, this will depend on several factors, such as how long it has been since your last dose, overall health status, and cancer stage. It is important not to double the dose to make up for a missed dose, as this can increase the risk of side effects.

  • Docetaxel

    Description

    This page contains brief details about the drug docetaxel, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

    Date of Approval

    Docetaxel is a chemotherapy medication that was approved to be used for its medical use on 19th May 2004.

    Mechanism of Action of Docetaxel

    Docetaxel works by inhibiting the microtubule structures found in the cells. These microtubules help the cancer cells in proliferating. Hence, inhibition of these structures aids in slowing down the growth of the cancer cells.

    Uses of Docetaxel

    Docetaxel is indicated for treating different types of cancers, which include the following, non-small cell lung cancer, breast cancer, prostate cancer, stomach cancer and head and neck cancer.

    Docetaxel Dosage available

    Docetaxel concentrate for solution for infusion (injections) is available in three doses of 20mg, 80mg and 120mg.

  • Crizotinib

    Description

    This page contains brief details about the drug crizotinib, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

    Date of Approval

    The U.S. FDA-approved Crizotinib to treat people with ALK-positive NSCLC in the year of 2011.

    Mechanism of Action of Crizotinib

    Crizotinib Capsule is a biological agent that acts as targeted drug therapy in cancer treatment. It is classified as a tyrosine kinase inhibitor. Anaplastic lymphoma kinase and ROS1 are two prominent genes that result in non-small cell lung cancer by undergoing mutation. Crizotinib acts by inhibiting these genes and stops the growth and development of cancer cells by shrinking them.

    Uses of Crizotinib

    Crizotinib capsule is indicated to treat the advanced stage of lung cancer as an initial treatment and is also recommended when other anticancer treatments did not work. It is prescribed to treat ALK-positive non-small cell lung cancer (NSCLC)

    Crizotinib Dosage available

    Crizotinib is available in 200mg and 250mg capsules. The recommended dose is 250mg twice daily, preferably one capsule each in the morning and evening. It is advisable to take this medicine at the same time each day with or without food. Swallow the capsule and do not crush, open, or dissolve them.